malignant tumor of nasopharynx
malignant tumor of nasopharynx
Explore linked clinical trials. Standard reference: MONDO:002131527 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, non-small cell lung carcinoma, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, prostate adenocarcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-09-21 | NCT05983432 | |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Stomatognathic Diseases, Thoracic Neoplasms, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung cancer, lung disorder, lung neoplasm, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-09-04 | NCT07038343 | |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, malignant tumor of nasopharynx, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 1 | 2026-08-11 | NCT07650266 | |
| Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment | Cancer of Oropharnyx, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, hypopharynx cancer, malignant tumor of nasopharynx, mouth disorder, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, squamous cell carcinoma, squamous cell neoplasm | Active, not recruiting | Phase 4 | 2026-07-13 | NCT07697287 | |
| Integrated Cancer Repository for Cancer Research | Abdominal Neoplasms, Adenomatous Polyps, Adnexal Diseases, Anal Cancer, Biliary Tract Neoplasms, Blood Protein Disorders, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cronkhite-Canada syndrome, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Duodenal Cancer, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Liver Neoplasms, Lynch syndrome, Male Urogenital Diseases, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplasms, Unknown Primary, Neoplastic Processes, Nose Neoplasms, Nutritional and Metabolic Diseases, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Peritoneal Diseases, Peritoneal Surface Malignancy, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Thymus Neoplasms, Thyroid Nodule, Unknown Primary Tumors, Urogenital Diseases, Urogenital Neoplasms, adenoma, anus disorder, anus neoplasm, benign urinary system neoplasm, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, cardiovascular disorder, central nervous system cancer, classic familial adenomatous polyposis, colonic disorder, colonic neoplasm, colorectal neoplasm, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, duodenal disorder, duodenum cancer, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gallbladder disorder, gallbladder neoplasm, gastric cancer, gastric neoplasm, gastrointestinal stromal tumor, gonadal disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary neoplastic syndrome, hypopharynx cancer, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, laryngeal disorder, laryngeal neoplasm, larynx cancer, leukemia, lip cancer, lip disorder, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, lymphatic system disorder, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant colon neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, malignant tumor of nasopharynx, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, metabolic disease, monoclonal gammopathy, mouth disorder, nasal cavity cancer, nasal disorder, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, nervous system disorder, neuroendocrine neoplasm, oral cavity cancer, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, paranasal sinus cancer, paranasal sinus disorder, paranasal sinus neoplasm, penile cancer, penile disorder, penile neoplasm, peritoneal neoplasm, plasma cell neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, small intestine cancer, stomach disorder, testicular cancer, testicular disorder, thymus cancer, thyroid gland disorder, thyroid tumor, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, vaginal cancer, vaginal disorder, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-06-29 | NCT02012699 | |
| Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | DNA Virus Infections, Epstein-Barr virus infection, Head and Neck Neoplasms, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Tumor Virus Infections, carcinoma, epithelial neoplasm, malignant tumor of nasopharynx, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, viral infectious disease | Active, not recruiting | Phase 2 | 2026-06-24 | NCT04925544 | |
| Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma | DNA Virus Infections, Epstein-Barr virus infection, Head and Neck Neoplasms, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Tumor Virus Infections, carcinoma, epithelial neoplasm, malignant tumor of nasopharynx, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, viral infectious disease | Recruiting | Not applicable | 2026-06-17 | NCT06682442 | |
| Trop2-targeted immunoPET Imaging of Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, cervix disorder, cholangiocarcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, head and neck cancer, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, thyroid gland disorder, thyroid tumor, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma, uterine disorder | Recruiting | Phase 2 / Phase 3 | 2026-05-29 | NCT06851663 | |
| Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 3 | 2026-04-13 | NCT07524413 | |
| The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Site, Nose Neoplasms, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, head and neck cancer, malignant tumor of nasopharynx, middle ear carcinoma, mouth disorder, nasal cavity and paranasal sinus carcinoma, nasal disorder, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, paranasal sinus disorder, paranasal sinus neoplasm, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder | Recruiting | Not stated | 2026-04-03 | NCT05483374 | |
| Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-02-25 | NCT05261750 | |
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck squamous cell carcinoma, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, non-small cell lung carcinoma, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, stomach disorder, urinary system disorder | Active, not recruiting | Phase 1 | 2026-02-09 | NCT05239143 | |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 3 | 2026-02-03 | NCT07385079 | |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 3 | 2026-01-28 | NCT07373990 | |
| Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2025-09-23 | NCT05305131 | |
| Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients | Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, prostate cancer, prostate disorder | Recruiting | Not stated | 2025-06-11 | NCT04340024 | |
| QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2025-05-22 | NCT06749899 | |
| Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2025-04-24 | NCT04875611 | |
| Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, malignant tumor of nasopharynx, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2025-01-23 | NCT05587374 | |
| Adebrelimab and Chemoradiotherapy in High-risk LANPC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, malignant tumor of nasopharynx, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2025-01-15 | NCT06349889 | |
| Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 2 | 2024-12-30 | NCT06414577 | |
| Arabic PRO Measures for Head and Neck Cancer Radiotherapy. | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, malignant tumor of nasopharynx, mouth disorder, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, squamous cell carcinoma, tongue cancer, tongue disorder | Recruiting | Not stated | 2024-10-29 | NCT06662929 | |
| U87 CAR-T in Patients With Advanced Head and Neck Tumors | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, head and neck cancer, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 1 | 2024-09-26 | NCT06614686 | |
| GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 2 | 2024-09-25 | NCT06611826 | |
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, malignant tumor of nasopharynx, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 2 | 2024-05-16 | NCT06019130 |